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ABSTRACT Human islet amyloid polypeptide (hIAPP) is the major component of amyloid plaques found in the pancreatic
islets of persons with type 2 diabetes mellitus. HIAPP belongs to the group of amyloidogenic proteins, characterized by their
aggregation and deposition as ﬁbrillar amyloid in various body tissues. The aggregation of amyloidogenic proteins is thought to
occur via a common pathway, but currently no unifying kinetic model exists. In previous work, we presented a model of amyloid
ﬁbril formation formulated from our observations of the aggregation of an amyloidogenic fragment of hIAPP, amino acids 20–29.
Our model is based on nucleation-dependent aggregation, modiﬁed by the formation of off-pathway hIAPP micelles. In the
present study we conﬁrm the presence of peptide micelles, and experimentally determine the critical micelle concentration in
solutions of hIAPP fragments using three different techniques: conductivity, pH, and ﬂuorescence. All three techniques yield
a critical micelle concentration of 3–3.5 mM peptide. Furthermore, based on changes in the ﬂuorescence intensity of a labeled
peptide fragment as well as a decrease in solution pH as a result of deprotonation of the amino terminus, we conclude that the
amino terminus of the fragment undergoes a signiﬁcant change of environment upon micellization.
INTRODUCTION
One of the signiﬁcant pathologies of type 2 diabetes mellitus
(type 2 DM) is the formation of extracellular amyloid
deposits in the b-cells of the islets of Langerhans in the
pancreas (Johnson et al., 1988; Westermark and Wilander,
1978). The primary component of these deposits is human
islet amyloid polypeptide (hIAPP) (Cooper et al., 1987),
a 37-amino acid peptide hormone that is normally produced
in, and secreted from, the b-cells, and functions to control
hyperglycemia by regulating the rate at which dietary glucose
enters the blood stream. The causal relationship between type
2 DM and the development of hIAPP amyloid deposits has
not yet been proven, though it is known that sites of hIAPP
amyloid deposition are surrounded by b-cell degeneration
and that solutions containing hIAPP ﬁbrils formed in vitro are
toxic to cultured human and rat islet b-cells (Lorenzo et al.,
1994).
HIAPP is one of a growing number of proteins and
peptides that are classiﬁed as amyloidogenic, referring to the
amyloid plaques formed by their deposition as highly or-
dered aggregates in the tissues of persons affected by one of
a variety of diseases. The mechanism of ﬁbril formation and
the general structure of the ﬁbrils are thought to be common
to all amyloidogenic proteins. The initial aggregates formed
are slender, unbranched ﬁbers that range from 3- to 8-nm in
diameter and up to several 100-nm in length (Goldsbury
et al., 1997; Harper et al., 1997b). Atomic force and electron
microscopies have been used to follow the self-assembly
of the elementary ﬁbrils to form a variety of differently
structured mature ﬁbrils, dependent upon such factors as
solvent conditions and the particular amyloidogenic protein
involved (Charge et al., 1995; Goldsbury et al., 2000; 1997;
Harper et al., 1997a,b). The mature ﬁbrils are characterized
by intermolecular antiparallel b-sheets, oriented roughly per-
pendicular to the axis of the ﬁbers, as seen with circular dich-
roism, nuclear magnetic resonance, and x-ray diffraction
(Blake and Serpell, 1996; Cohen and Calkins, 1959; Cort
et al., 1994;Grifﬁths et al., 1995;Kirschner et al., 1986; Sunde
et al., 1997).
To gain a full understanding of the process of amyloid
formation, it is crucial not only to characterize the structure
of the ﬁbrils, but also to develop a kinetic model that describes
how these ﬁbrils are formed. There is signiﬁcant evidence that
amyloid ﬁbril formation is a nucleation-dependent process
(Ashburn et al., 1992; Jarrett and Lansbury, 1992, 1993;
Lomakin et al., 1996) (depicted in Fig. 1A) and thereby resem-
bles other ordered protein aggregation processes such as pro-
tein crystallization (Blow et al., 1994), sickle cell hemoglobin
polymerization (Mirchev and Ferrone, 1997), and viral coat
protein assembly (Schuster et al., 1979). The nucleation-
dependent aggregation process is initiated by the forming of
a nucleus, deﬁned as the smallest, marginally stable, struc-
tured aggregate created by the concerted association ofmono-
mers. Because there is a high entropic barrier to nucleation, it
is the rate-limiting step in the aggregation process, giving rise
to a distinct lag time before aggregation is initiated. However,
once a nucleus is formed, the addition of monomers to the
growing aggregate is favorable (in Fig. 1 A, Kb  Ka) and
aggregation proceeds rapidly. Since nucleation is a high-order
reaction, it is expected to depend strongly upon the concen-
tration of the protein. More precisely, for a nucleus consisting
of j-monomers, the lag time is expected to be inversely
proportional to the total protein concentration to the ( j1 1)th
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power (Oosawa and Kasai, 1962). Thus, small changes in the
total protein concentration result in dramatic changes in the
aggregation lag time, even for nuclei consisting of only three
or four monomers. A striking example is the initiation of
sickle cell hemoglobin polymerization, which is highly
concentration-dependent, so that a twofold dilution of the
protein concentration prolongs the lag time some 10-billion-
fold (Ferrone et al., 1985). The lag phase can be eliminated by
the addition of preformed nuclei, or seeds, to a monomeric
protein solution.
Describing the kinetics of aggregation of amyloidogenic
peptides and quantiﬁcation of intermediates on the aggrega-
tion pathway has proven to be challenging for two major
reasons. The ﬁrst reason is that to accurately describe early
stages in the aggregation process, initial peptide solutions
must be fully monomeric, as it has been shown by many
groups that the presence of even a small amount of seed
material results in immediate aggregation of the peptide
(Come et al., 1993; Jarrett and Lansbury, 1993; Snyder et al.,
1994; Wood et al., 1996). Despite this, relatively few studies
have emphasized this point or made serious efforts to ensure
fully monomeric solutions (Jarrett and Lansbury, 1992;
Rhoades et al., 2000; Walsh et al., 1999). Not only do the
seeds eliminate the initial stages of aggregation (nucleation),
they also make it difﬁcult to obtain reproducible initial
conditions, as varying amounts of seeds may be found in
different preparations. The second reason is that many
methods traditionally used to follow amyloid formation,
such as turbidity or dye binding, are incapable of detecting
early intermediates. Since these aggregation intermediates
are small, and usually present in low concentrations, they
are frequently below the threshold of detection by turbidity.
Likewise, if the intermediates have different secondary
structures than the mature ﬁbrils, then dyes such as Congo
Red and Thioﬂavin T, which bind to the interstrand b-sheets
of the mature ﬁbrils, will not detect these intermediates. A
number of kinetic models based on dynamic light scattering
have been proposed for the aggregation of the amyloidogenic
peptide associated with Alzheimer’s disease, Ab (Lomakin
et al., 1996, 1997; Pallitto and Murphy, 2001; Tomski and
Murphy, 1992), but a general model is still lacking.
In our previous work, we focused on characterizing the
initiation of aggregation of a fragment of hIAPP in terms of
its lag time before detectable aggregation occurs (Rhoades
et al., 2000). We found that for a wide range of peptide
concentrations, ;5 mM–150 mM, under conditions where
we were conﬁdent that our initial solutions contained only
monomeric peptide, the lag time was independent of the total
concentration of the peptide, in direct contradiction to what
is predicted for nucleation dependent aggregation. To ex-
plain our observations, we developed a modiﬁed model of
nucleation-dependent aggregation, shown in Fig. 1 B. In this
model, off-aggregation-pathway peptide micelles are formed
at peptide concentrations greater than the critical micelle con-
centration (CMC). The formation of micelles helps maintain
the monomer concentration at the CMC since whenever the
total peptide concentration exceeds the CMC, all excess
peptide is incorporated into micelles. Nuclei are formed only
frommonomeric peptide interactions, as in the classic nuclea-
tion-dependent aggregationmodel (Fig. 1A), and thus nuclea-
tion depends only on the concentration ofmonomeric peptide.
Therefore, for concentrations greater than the CMC, the
lag time does not exhibit a dependence upon the total pro-
tein concentration. If the micelles were on-pathway (i.e., they
give rise to nuclei), then we would expect to see some de-
pendence of the lag time upon the peptide concentration,
as explained in the following. An increase in the peptide
concentration results in an increase in the number of micelles
in solution. A higher concentration of micelles results in
more rapid nucleus formation, and a consequent decrease in
the lag time to aggregation. However, as we do not see a
dependence of the lag time upon the concentration of pep-
tide, then the micelles must be off-pathway. Further evidence
that our model may serve as the basis for a general one de-
scribing amyloid aggregation comes from recent kinetic
studies which show that the aggregation of full-length hIAPP
(Padrick and Miranker 2002), as well as prion protein Sup 35
(Serio et al., 2000), are concentration-independent.
The presence of off-pathway peptide micelles is a key, but
hitherto unproven, component of our hIAPP aggregation
model (Fig. 1 B). Thus, the aim of this study was to experi-
mentally test for the presence of hIAPP micelles in solution
using approaches that have been previously applied for the
characterization of conventional micelle-forming solutions.
It is well established that many physiochemical properties
of such solutions change abruptly at the CMC (Hiemenz
FIGURE 1 (A) Schematic representation of nucleation-dependent aggre-
gation. The nucleus forms from the slow association of j-monomers. Its rate
of formation thus depends on the ( j 1 1)th power of the monomer con-
centration. In contrast, the addition of monomers to the nucleus or to the
growing polymers is favorable and proceeds rapidly (adapted from Jarrett
and Lansbury, 1993). (B) Schematic representation of nucleation-dependent
aggregation with off-pathway micelles. Above the critical micelle concen-
tration, monomers and micelles exist in a rapid equilibrium that maintains
a constant monomer concentration. The nucleus is formed from monomer
peptide-peptide interactions. (C) Amino acid sequence of human islet
amyloid polypeptide, with amino acids 20–30 underlined, hydrophilic resi-
dues marked with open circles, and hydrophobic residues marked with solid
circles.
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and Rajogopalan, 1997), including but not limited to: light
scattering,viscosity,surface tension,absorption,ﬂuorescence,
conductivity, and pH. To determine the CMC of a micelle-
forming substance, one of these properties is monitored as
a function of concentration and a change in the slope of the
plot made from the data marks the CMC.
In the study presented here, we conﬁrm the presence
of micelles formed by hIAPP fragments in solution, and
determine the CMC with three independent techniques: con-
ductivity, pH, and ﬂuorescence intensity. Three fragments
of hIAPP were used: amino acids 20–30 (hIAPP 20–30),
20–29 with a tryptophan (Trp) at the carboxyl terminus
(hIAPP 20–29-Trp), and 20–29 with a ﬂuorescein at the
amino terminus (hIAPP ﬂuo-20–29). Previous studies have
established that hIAPP fragments containing residues 20–29
may serve as suitable model systems for in vitro amyloid
formation since these fragments are capable of forming
amyloid ﬁbrils in vitro that are indistinguishable from (and
exhibit many of the amyloidogenic characteristics of) ﬁbers
formed by the full-length peptide (Fig. 1 C) (Ashburn et al.,
1992; Charge et al., 1995; Glenner et al., 1988; Westermark
et al., 1990). The tryptophan and ﬂuorescein groups were
added to two of the fragments to serve as ﬂuorescent probes
of the carboxyl and amino termini, respectively.
MATERIALS AND METHODS
The fragments hIAPP 20–30, hIAPP 20–29-Trp, and rat IAPP 20–29 (rIAPP
20–29) were synthesized by the Protein and Carbohydrate Core Facility
(University of Michigan, Ann Arbor) and were puriﬁed by reversed-phase
high-performance liquid chromatography to[98% purity. hIAPP ﬂuo-20–
29 was purchased from Bio-Synthesis Incorporated (Lewisville, TX).
Though these peptide fragments show slight differences in their solubilities,
turbidity measurements show that the aggregation of each of these peptides
is concentration-independent between ;5 and 150 mM, and characterized
by a lag phase of ;40 h before detectable aggregation. This behavior
corresponds to our previously published data (not shown) (Rhoades et al.,
2000). Moreover, at the concentration range used, the length of this lag
phase was concentration-independent. Experiments were repeated a mini-
mum of ﬁve times, and the data presented here is the average of at least ﬁve
experiments.
The hIAPP fragments were dissolved in 100% dimethyl sulfoxide
(DMSO) to create stock solutions of 20 mM. The stock solutions were stored
at20 C. When needed, the necessary amount of peptide was removed from
the DMSO stock and diluted into 25 mM KCl. The concentration of DMSO
is 0.1% throughout all the experiments, which did not affect the aggregation
of the fragments (data not shown). The solutions were ﬁltered through a 0.2-
mm Acrodisc syringe ﬁlter (Pall Gelman Sciences, Ann Arbor, MI) to
remove dust and other particulate matter.
Conductivity measurements were made using a Cole-Parmer Digital
conductivity meter, with a gold-plated dip cell with a built-in thermistor
(Vernon Hills, IL). The pH of the solutions was measured indirectly by using
a pH-sensitive dye, Bromcresol Purple (BP), from Sigma Chemical Com-
pany (St. Louis, MO). The absorption spectrum of BP changes over a range
of pH 5.2–6.8 which we found to be suitable for our experiments. Absorp-
tion measurements of the BP/hIAPP fragment solutions were made with a
Shimadzu UV-Vis spectrophotometer and the ratio Abs587/Abs430, which
is particularly sensitive to pH changes, was used. Fluorescence emission
measurements of hIAPP 20–29-Trp and hIAPP ﬂuo-20–29 were made with a
Spex model Fluorolog II ﬂuorimeter. The hIAPP 20-29-Trp was excited at
290 nm and the emission from 300 to 400 nmwas recorded. The hIAPP ﬂuo-
20–29 was excited at 465 nm and the emission collected from 475 to 600 nm.
All measurements were made at room temperature.
A 20-mM solution of the appropriate hIAPP fragment was prepared
by diluting 1 ml of the 20-mM stock solution into 1 mL of 25 mM KCl. As
we mention in the Introduction, our previous work characterized the
aggregation of hIAPP fragment solutions over a range of concentrations
for 5 mM to 150 mM, ﬁnding that these solutions remained kinetically
soluble for a period of ;40 h. However, these solutions were prepared by
diluting the stock solutions of hIAPP fragments in DMSO into 10 mM
sodium phosphate buffer pH 7, with 10 mM NaCl. For the studies presented
here, we use ddH2O rather than buffer, as buffer interferes with both the
conductivity and pH measurements. Thus we chose 20 mM as the highest
peptide concentration because it was determined that this value represents
the solubility limit of the hIAPP fragments in pure ddH2O. Higher
concentrations of peptide diluted into ddH2O resulted in irreproducible
behavior, and often in rapid, visible, insolubilization of the peptide. The
measurements of conductivity, absorption, and ﬂuorescence were carried out
in one of the following two ways: 1), A measurement of the signal from
a peptide solution was made, then the sample was diluted to the next desired
concentration with 25 mM KCl/0.1% DMSO. And 2), Each concentration
was prepared by direct dilution of the initial 20 mM peptide solution to the
desired concentration and each sample was then measured. Both methods
gave comparable, reproducible results. The dilutions were repeated until the
concentration was too low for reproducible measurements to be obtained.
For the absorption studies, 2 mL of a 5-mM stock of BP were added to 1 mL
of the 20-mMpeptide solution, for a ﬁnal dye concentration of 10 mM. These
samples were diluted with 25 mMKCl/0.1%DMSO/10 mMBP.We observe
that solutions of 20 mM hIAPP in ddH2O or 25 mM KCl are kinetically
soluble (i.e., no detectable seeds or aggregates form) for close to 40 h. As all
measurements were made within an hour after diluting the peptide stocks
into aqueous solution, we do not expect seed formation or aggregation to be
an issue for either serially diluted or directly diluted solutions.
RESULTS
Fresh solutions of hIAPP 20–30, hIAPP 20–29-Trp, and
hIAPP ﬂuo-20–29, prepared as described in Materials and
Methods, were free of all amyloidogenic material as veriﬁed
by their reproducible aggregation behavior, explained in
detail in our previous work (Rhoades et al., 2000). As men-
tioned, under our experimental conditions, we consistently
observed a lag time of;40h for the hIAPP fragment, conﬁrm-
ing that the solutions were initially free from nuclei and other
amyloidogenic material.
Fig. 2 shows the conductivity of hIAPP 20–30 solutions
as a function of peptide concentration. The CMC, which is
particularly clearly marked by a change in slope from positive
to negative (see Discussion), is ;3.5 mM. As will be dis-
cussed later, the shape of the conductivity curve of hIAPP
20–30 in 25 mM KCl resembles the conductivity curve of
sodium dodecyl sulfate (SDS), a well-characterized micellar
system, in 6 mMHCl. The conductivity of solutions of rIAPP
20–29 (which does not aggregate) was measured as a control,
with no evidence of micelles observed (data not shown).
BP absorption ratio versus peptide concentration is shown
in Fig. 3. As with the conductivity measurements, a clear
change in slope is observed, and the CMC value determined
from this break is ;3 mM, in very good agreement with the
conductivity data. Although the data is plotted as absorbance
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ratio of BP, these values correspond to the changing pH of
the solutions, i.e., an increase in the absorbance ratio cor-
responds to a decrease in solution pH. It is clear from Fig. 3
that the slope of the absorption ratio versus peptide concen-
tration is larger above the CMC than below this value. This
indicates that the pH decreases more rapidly at concentra-
tions above the CMC, where the micelle concentration
increases with increasing peptide concentration while the
monomer concentration remains constant. The micellization,
therefore, is associated with an increase in H1 ions released
into solution. If the change in pH observed for hIAPP 20–30
solutions were merely due to a change in the ionic strength of
the unbuffered solution (due to, for example, an increase in
the amount of salt from the lyophilized peptide, proportional
to the increasing amount of peptide), then one would expect
the relationship between concentration and pH to be a simple
linear one.
The data in Fig. 4 shows the change in the ﬂuorescence
intensity of the ﬂuorescein and tryptophan-labeled hIAPP
20–29 as a function of peptide concentration. The emission
intensity of hIAPP ﬂuo-20–29 reveals a deﬁnite change in
the slope at ;3 mM peptide, also in very good agreement
with both the conductivity and pH measurements. Further-
more, as the ﬂuorescein serves as a probe of the amino
terminus of the peptide, this data indicates that this terminus
experiences a change in its environment upon micellization.
We cannot draw any deﬁnite conclusions from the data for
hIAPP 20–29-Trp since the ﬂuorescence intensity increases
linearly with peptide concentration. This can be rationalized
in two ways: 1), the carboxyl terminus does not change
environment upon micellization; or 2), the tryptophan
ﬂuorescence is insensitive to changes in the chromophore’s
environment upon micellization.
DISCUSSION
Conductivity has been frequently used to determine the
CMC of ionic solutions and is considered to be one of the
most effective methods for doing so (Mukerjee and Mysels,
1971). Using this approach we measure a CMC of;3.5 mM
for hIAPP 20–30 in 25 mM KCl. As mentioned in Results,
FIGURE 4 Fluorescence intensity of hIAPP ﬂuo-20–29 (open circles)
and hIAPP 20–29-Trp (solid circles) as a function of peptide concentration.
The hIAPP ﬂuo-20–29 was excited at 465 nm and the emission intensity at
515 nm is plotted. The hIAPP 20–29-Trp was excited at 290 nm and the
emission intensity at 350 nm is plotted. The hIAPP ﬂuo-20–29 shows a clear
change in slope at ;3 mM peptide, indicating that the amino terminus
undergoes a change in environment upon micellization. The line shown is
a linear ﬁt to the data from hIAPP ﬂuo-20–29 concentrations[5 mM.
FIGURE 3 Bromcresol Purple absorption as a function of hIAPP 20–30
concentration. The absorbance values at 430 nm and 587 nm of the hIAPP
20–30/BP solutions are plotted as a normalized ratio absorbance (587 nm/
430 nm). The CMC is;3 mM, as determined by a change in the slope of the
plot. Increasing normalized absorbance intensity is inversely proportional to
pH: the solutions become more acidic with increasing hIAPP 20–30
concentration. The line shown is a linear ﬁt to data from hIAPP con-
centrations[5 mM.
FIGURE 2 Conductivity as a function of hIAPP 20–30 concentration.
The change in slope of the curve at ;3.5 mM is interpreted as the CMC of
the solution.
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the shape of the curve closely resembles that of SDS in 6 mM
HCl, for which equations have been derived and presented
by Dominguez and co-workers (Dominguez et al., 1997). In
their model, the change in slope of the conductivity versus
concentration curve, from positive to negative, at the CMC is
due to the fact that the forming SDS micelles carry a high
density of negative charge on their surface and attract
cations, thereby reducing their mobility and leading to de-
creased conductivity. This negative slope persists for a range
of concentrations immediately above the CMC, but at higher
concentrations, when cation capture is saturated, the slope
reverts to a positive one. Our explanation of the results
presented in Fig. 2 is that the behavior of the hIAPP 20–30
micelle system in presence of KCl is similar to that described
by Dominguez and co-workers for SDS in presence of HCL,
and thus that the equations presented by these authors can
be used to describe our results. We refer the reader to the
Dominguez and co-workers publication for a more detailed,
quantitative, description of micellization in the presence of
counterions. While we do not know the exact characteristics
of the hIAPP micelles, i.e., how many monomers are asso-
ciated, to what extent the micelles are ionized upon forming,
what concentrations of counter ions associate with them, etc.,
the conductivity data shown in Fig. 2 clearly indicate the
CMC value.
It is also important to mention that due to the nature of
the hIAPP fragments, we were limited in the parameters we
could vary in our conductivity measurements. As described
in Materials and Methods, the solubility limit of hIAPP 20–
30 in 25 mMKCl is;20 mM. Thus we were not able to mea-
sure the conductivity of solutions at higher concentrations,
although we expect that the value should resume its increase.
Additionally, we were unable to vary the KCl concentration
substantially. At higher concentrations of KCl, the conduc-
tivity of this salt overwhelms that of the hIAPP fragments.
We did attempt to measure the conductivity of hIAPP 20–30
in solutions with very low (5 mM) or no KCl. Though we
found that these measurements were somewhat irreproduc-
ible (most likely due to the low concentrations of ions), the
overall shape of the plots resembled conductivity plots of
SDS in the absence of HCl: a line with a positive slope that
changes at the CMC, to a line with a slightly lower, but still
positive, slope (data not shown). Thus, the behavior of hIAPP
20–30, as measured by conductivity, in the absence and
presence of KCl appears to be very similar to that of SDS in
the absence and presence of HCl. This conﬁrms that our
conductivity measurements indeed report on the presence of
hIAPP micelles in solution.
Though in Fig. 1 B we depict the micelles as resembling
traditional amphipathic structures, at present we do not have
a physical model for the overall shape or size of the micelles.
We thus use the term ‘‘micelle’’ to loosely describe the
structures formed by rapid, reversible, nonﬁbrillar oligomer-
ization of the hIAPP fragment. During amyloid formation, as
monomer peptide is depleted by being incorporated ﬁrst into
nuclei and then into growing ﬁbrils, the micelles disassem-
ble. The term ‘‘micelle’’ has been used to describe oligo-
meric structures formed by other amyloidogenic peptides.
Before our work, Lomakin and co-workers used the term
‘‘micelle’’ to describe on-pathway oligomeric intermediates
formed by the Alzheimer’s Ab peptide that give rise to
nuclei and then ﬁbrils (Lomakin et al., 1996, 1997). More
recently, Serio and co-workers describe off-pathway oligo-
meric structures formed by the prion protein Sup35 as
‘‘micellelike’’ in their kinetics (Serio et al., 2000). Initial
studies by both Harper et al. (1997b) and Walsh et al. (1997)
proposed that one possible role for the oligomeric structures
formed by Ab, termed protoﬁbrils, is to serve as off-pathway
peptide reservoirs, kinetic entities much like our micelles.
Thus, we use the term as a useful kinetic description and not
necessarily to imply that the hIAPP 20–29 forms traditional
micellar structures. We also use the term to emphasize the
difference between off-pathway oligomers (the micelles) and
other small oligomers, such as seeds or small aggregates that
are found on-pathway.
The CMC we measured with conductivity was conﬁrmed
by pH/absorbance and ﬂuorescence intensity measurements,
both showing the CMC to be ;3 mM. In addition to corro-
borating the conductivity measurements, these two techni-
ques also yield some information about the structure of the
micelles. From the pH/absorption we can determine that
solutions of hIAPP 20–30 ( pKa  5.5) in 25 mM KCl are
increasingly more acidic with increasing peptide fragment
concentration. Above the CMC, the pH decreases more
sharply, as indicated by an increase in the slope of the plot of
BP absorbance versus hIAPP 20–30 concentration (Fig. 3).
The increasing acidity indicates that enhanced release of H1
ions into solution occurs upon micellization, an effect that
has been previously observed with other micelle-forming
peptides (Kumar et al., 1996; Mandal and Jayakumar, 1994).
Because the fragment hIAPP 20–30 does not contain any
titratable side groups (see Fig. 1 C for the amino acid se-
quence of hIAPP), the only likely candidates for deprotona-
tion are the terminal amino and carboxyl groups. At neutral
pH, the carboxyl groups ( pKa ;3.1) are fully deprotonated,
making the amino terminus the likely proton donor. A
plausible explanation of this observation is that upon mi-
cellization, the amino termini of the peptide fragments come
into close proximity with each other, resulting in a decrease
of the pKa of the NH3
1 groups with consequent partial
deprotonation of these groups, and a decrease in the pH of
the solution.
The ﬂuorescently-labeled peptides provide further evi-
dence for the involvement of the amino terminus in the
micellization. hIAPP ﬂuo-20–29 and hIAPP 20–29-Trp were
used to probe the environments of the amino and carboxyl
termini, respectively, of the peptide. The linear relationship
between the Trp ﬂuorescence intensity and the peptide con-
centration indicates that the environment of the carboxyl
terminus does not change signiﬁcantly upon micellization.
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Time-resolved ﬂuorescence anisotropy data of hIAPP 20-29-
Trp (data not shown) displays an extremely rapid decay,
indicating that the Trp has free rotational movement in
solution, and therefore that the carboxyl terminus is solvent-
exposed. Conversely, the ﬂuorescence of hIAPP ﬂuo-20–29
indicates that the amino terminus does undergo a change of
environment upon micellization. It is well known that ﬂuo-
rescein emission intensity sharply decreases upon removal
from aqueous to less polar solvents. The data in Fig. 4 show
that the ﬂuorescence intensity per unit of hIAPP ﬂuo-20–29
decreases above the CMC, as evidenced by a decrease in the
slope of the plot. An explanation for this decrease is that the
environment of the amino terminus in the micelle is not as
polar as the environment of the amino terminus free in sol-
ution. This is expected if the amino terminus is internalized
into the micelle. Thus, the model we propose for hIAPP
fragment micelles based on our pH and ﬂuorescence data
has the amino terminus incorporated into the interior of
the micelle, bringing the amino termini of adjacent peptides
into proximity of each other, as well as into a hydrophobic
environment, thus resulting in deprotonation of the NH3
1
groups.
One major area of interest is the characterization of the
size of the micelles; however, this has proven to be chal-
lenging primarily due to the heterogeneity and small size of
these structures and the need to work with low concentra-
tions of the small peptide. Thus, although we were able to
visualize the ﬁbrils formed by the hIAPP fragments (by elec-
tron microscopy), we were not able to visualize the micelles,
which are dynamic, polydisperse structures in rapid equilib-
rium with monomeric peptide. By their nature, the micelles
are sensitive to changes in their environment and may disas-
semble upon contact with the electron microscopy substrate,
due to changes in local monomer concentration. Another
classical method for characterizing protein self-association,
dynamic light scattering, has also proven inadequate for
characterizing the structures formed by hIAPP 20–30. Even
at a concentration of ;200 mM hIAPP 20–30 (;0.22 mg/
mL; this concentration is used because, as noted in our
previous work—Rhoades et al. (2000)—it is close to highest
concentration at which we observe reproducible aggregation
and represents the solubility limit of hIAPP 20–30 diluted
from DMSO into a neutral aqueous solution) we were unable
to obtain a correlation signal for the micelles, indicating that
the maximum concentration is still far too low to be detected
by light scattering. Additionally, we hypothesize, based on
the detection limit of our turbidity studies, that the micelles
are composed of not more than 50 monomers, and thus their
diffusion may be too rapid to be detected by the correlator.
We show in this work that are able to measure the CMC of
hIAPP fragment micelles using techniques well-established
for characterizing micellar systems, indicating the potential
to use such methods for the study of peptidal systems. It is
particularly noteworthy that the CMC value of 3–3.5 mM
that we have measured by three independent techniques is in
agreement with two of our original observations regarding
hIAPP fragment aggregation (Rhoades et al., 2000). First,
reproducible, concentration-independent aggregation occurs
at concentrations greater than ;5 mM peptide. Second, the
critical concentration for hIAPP 20–29 aggregation, Cc, was
measured by us to be;1 mM. Thus, we expect that the CMC
should fall in between these measured values, which is
indeed where it is found. Current efforts in our lab are being
made to characterize the concentration-dependence of hIAPP
fragments at sub-CMC concentrations.
References to the in vitro nonﬁbrillar oligomerization
of amyloidogenic proteins have long been found in the
literature, describing species ranging in size from dimers to
large, amorphous structures (Garzon-Rodriguez et al., 1997;
Harper et al., 1997b; Huang et al., 2000; Levine, 1995;
Lomakin et al., 1996; Tjernberg et al., 1999; Walsh et al.,
1997). However, it is only relatively recently that a possible
functional role for amyloid oligomers in amyloid disease
pathology has been proposed based on growing evidence
from in vivo studies. In particular, these studies have re-
vealed that the toxic forms of several amyloidogenic
peptides (including hIAPP) are oligomeric structures, rather
than the fully aggregated amyloid ﬁbrils as originally
thought (Bhatia et al., 2000; Johnson et al., 1988; Lambert
et al., 1998; Zhu et al., 2000). The studies showed that
freshly prepared peptide solutions are cytotoxic, indicating
the immediate presence of oligomeric species in solution.
Earlier studies indicated that the ﬁbrils themselves were the
cytotoxic form of amyloid peptides (Fraser et al., 1994;
Lorenzo et al., 1994). However, as the importance of
nonﬁbrillar oligomeric species was not recognized at the
time, no care was taken to separate this material from the
ﬁbrils, and the cytotoxic preparations probably contained
a mixture of ﬁbrillar and nonﬁbrillar oligomers.
Also of interest is a recent study of two mutants of the
amyloidogenic protein, a-synuclein, that are linked to early-
onset Parkinson’s disease (Conway et al., 2000). This study
compared the aggregation of these two mutants with the
wild-type protein and found that the common property of
the mutants was not the rate of ﬁbrillization, but the rate of
nonﬁbrillar oligomerization, which was more rapid for both
of the mutants than the wild-type. The studies mentioned
above raise the possibility that amyloid ﬁbrils and plaques
are relatively harmless products, while the nonﬁbrillar oligo-
mers cause most of the damage to the cells. If this idea is
borne out, therapeutic techniques, which have thus far been
aimed at the prevention of ﬁbril formation, may instead focus
on preventing the formation of micelles by amyloidogenic
peptides.
The present study utilized an amyloidogenic fragment of
hIAPP and the question of the biological relevance of
a model based on this fragment is an important one. We thus
use caution in drawing any conclusions of biological sig-
niﬁcance based on our simpliﬁed in vitro model. As noted in
the Introduction, ﬁbrils formed by hIAPP 20–29, as well
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as shorter hIAPP fragments within the 20–29 region, are
indistinguishable from those formed by full-length hIAPP
1–37 (Ashburn et al., 1992; Azriel and Gazit, 2001; Charge
et al., 1995; Glenner et al., 1988; Westermark et al., 1990).
Additionally, it was recently shown that preparations of these
shorter sequences, hIAPP 22-27 and hIAPP 20-27, as well as
hIAPP 20-29, are cytotoxic to rat insulimona cells (Tenidis
et al., 2000). Based on these observations, we cannot state
with certainty that the aggregation behavior of the fragment
is the same as the full-length peptide, but it is clear that it can
serve as a useful model in understanding the mechanism un-
derlying amyloidogenesis. It is interesting to note that a num-
ber of recent studies of hIAPP and Ab aimed at inhibiting
their aggregation used short, 5–12 amino acid, regions of
these peptides with great success (Ghanta et al., 1996;
Hughes et al., 2000; Scrocchi et al., 2002; Soto et al., 1996).
While evidence accumulates pointing toward nonﬁbrillar
oligomers rather than ﬁbrils as the cytotoxic culprits, raising
the question whether preventing amyloid formation is the
ultimate goal of therapeutics, all these studies nevertheless
demonstrate that the short peptides do provide good target
sequences for any studies aimed at understanding, or
controlling, the aggregation process.
Despite the great effort put into characterizing the
aggregation of amyloidogenic proteins, the process is still
not well understood and no kinetic model exists which can
serve as a general description of amyloidogenesis. In the pre-
sent study we present experimental evidence for the forma-
tion of micelles by fragments of hIAPP, an observation that
strongly supports our previously proposed model for the ag-
gregation of these peptides, which postulates off-pathway
peptide micelles. Current efforts in our laboratory aim at
further characterization of the micelles as well as obtaining
deeper insight into hIAPP fragment aggregation.
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